India's Glenmark spinning out innovative assets into U.S. unit
Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization.
The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO and an independent board. It will house eight assets from its India-based parent -- three in preclinical testing and five in the clinic -- across oncology, immunology and pain management. ...
BCIQ Company Profiles
BCIQ Target Profiles
Epidermal growth factor receptor (EGFR) (ErbB1) (HER1)
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Microsomal prostaglandin E synthase-1 (PTGES) (mPGES-1)
Transient receptor potential A1 (TRPA1)
Tumor necrosis factor (TNF) receptor superfamily member 4 (OX40) (TNFRSF4) (CD134)